NASDAQ:TRIL

Trillium Therapeutics Stock Forecast, Price & News

$12.90

-0.23 (-1.75 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.70

Now: $12.90▼

$13.27

50-Day Range

$11.63

MA: $13.77▼

$17.04

52-Week Range

$2.50

Now: $12.90▼

$20.96

Volume726,620 shs

Average Volume1.38 million shs

Market Capitalization$1.33 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.27

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

MarketRank^™

Overall MarketRank^™

1.72 out of 5 stars

Medical Sector

183rd out of 1,925 stocks

Pharmaceutical Preparations Industry

93rd out of 773 stocks

3.4 Analyst's Opinion

Consensus Rating
Trillium Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.25, Trillium Therapeutics has a forecasted upside of 64.7% from its current price of $12.90.
Amount of Analyst Coverage
Trillium Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Trillium Therapeutics has received 301 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trillium Therapeutics has received 213 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trillium Therapeutics has received 58.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote “Outperform” if you believe TRIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Trillium Therapeutics does not currently pay a dividend.
Dividend Growth
Trillium Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trillium Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $558,755.00 in company stock.
Percentage Held by Institutions
67.46% of the stock of Trillium Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Trillium Therapeutics are expected to grow in the coming year, from ($2.42) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trillium Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trillium Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TRIL

Previous Symbol

CUSIPN/A

CIK1616212

Webwww.trilliumtherapeutics.com

Phone416-595-0627

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio22.44

Quick Ratio22.44

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$120,000.00

Price / Sales11,064.55

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.86) per share

Price / Book-15.00

Profitability

EPS (Most Recent Fiscal Year)($1.38)

Net Income$-41,620,000.00

Net MarginsN/A

Return on Equity-70.00%

Return on Assets-28.84%

Miscellaneous

Outstanding Shares102,926,000

Market Cap$1.33 billion

Next Earnings Date3/9/2021 (Estimated)

OptionableOptionable

$12.90

-0.23 (-1.75 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

How has Trillium Therapeutics' stock been impacted by Coronavirus?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 148.6% and is now trading at $12.90.
View which stocks have been most impacted by COVID-19.

Is Trillium Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trillium Therapeutics stock.
View analyst ratings for Trillium Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Trillium Therapeutics?

Wall Street analysts have given Trillium Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Trillium Therapeutics' CEO?

1,448 employees have rated Trillium Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Trillium Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Trillium Therapeutics.

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its earnings results on Sunday, November, 15th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.33.
View Trillium Therapeutics' earnings history.

What price target have analysts set for TRIL?

5 equities research analysts have issued 1-year price objectives for Trillium Therapeutics' stock. Their forecasts range from $14.00 to $28.00. On average, they anticipate Trillium Therapeutics' stock price to reach $21.25 in the next year. This suggests a possible upside of 64.7% from the stock's current price.
View analysts' price targets for Trillium Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting Trillium Therapeutics?

Trillium Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totaling 9,770,000 shares, an increase of 29.7% from the December 15th total of 7,530,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 5.0 days. Approximately 12.3% of the company's shares are short sold.
View Trillium Therapeutics' Short Interest.

Who are some of Trillium Therapeutics' key competitors?

Some companies that are related to Trillium Therapeutics include Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Arena Pharmaceuticals (ARNA), Atea Pharmaceuticals (AVIR), ChemoCentryx (CCXI), GW Pharmaceuticals (GWPH), FibroGen (FGEN), PTC Therapeutics (PTCT), Insmed (INSM), Arvinas (ARVN), Hypera (HYPMY) and Reata Pharmaceuticals (RETA).
View all of TRIL's competitors.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:

Dr. Jan Skvarka, Pres, CEO & Director
Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 55, Pay $351.27k)
Dr. Robert Uger, Chief Scientific Officer
Dr. Penka Petrova, Chief Devel. Officer
Dr. Rosemary Harrison, Sr. VP of Corp. Devel. & Strategy
Dr. Michael G. Hill, Head of Calgary Site
Ms. Kathleen Large, Sr. VP - Clinical Operations (Age 60)
Dr. Ingmar Bruns M.D., Ph.D., Chief Medical Officer

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Who are Trillium Therapeutics' major shareholders?

Trillium Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Columbus Circle Investors (0.43%), FNY Investment Advisers LLC (0.08%), Vigilare Wealth Management (0.03%) and Private Capital Advisors Inc. (0.02%). Company insiders that own Trillium Therapeutics stock include James T Parsons, Jan Skvarka, Penka Petrova and Robert Uger.
View institutional ownership trends for Trillium Therapeutics.

Which major investors are buying Trillium Therapeutics stock?

TRIL stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, FNY Investment Advisers LLC, Private Capital Advisors Inc., and Vigilare Wealth Management.
View insider buying and selling activity for Trillium Therapeutics or or view top insider-buying stocks.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $12.90.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of $1.33 billion and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here